Table 3.
18q LOH Status and Patient Mortality in 532 Stage I to IV Non–MSI-High Colorectal Cancer
| 18q LOH Status | Total No. | Colorectal Cancer-Specific Mortality |
Overall Mortality |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Events | Person-Years | Univariate HR | 95% CI | Stage-Matched HR | 95% CI | Multivariate HR | 95% CI | Events | Person-Years | Univariate HR | 95% CI | Stage-Matched HR | 95% CI | Multivariate HR | 95% CI | ||
| 18q LOH negative | 184 | 55 | 1,404 | 1 | Referent | 1 | Referent | 1 | Referent | 87 | 1,404 | 1 | Referent | 1 | Referent | 1 | Referent |
| 18q LOH positive | 348 | 100 | 2,659 | 0.96 | 0.69 to 1.33 | 1.00 | 0.71 to 1.41 | 1.18 | 0.81 to 1.71 | 152 | 2,659 | 0.92 | 0.71 to 1.20 | 0.94 | 0.72 to 1.24 | 1.03 | 0.77 to 1.38 |
NOTE. The multivariate, stage-matched (stratified) Cox regression model included age, year of diagnosis, sex, family history of colorectal cancer, tumor location, tumor grade, KRAS, BRAF, PIK3CA,p53, β-catenin, JC virus T antigen, LINE-1 methylation, MSI (low v microsatellite stability), and CpG island methylator phenotype.
Abbreviations: LOH, loss of heterozygosity; MSI, microsatellite instability; HR, hazard ratio.